Most public discussion about psychedelic therapy focuses on the treatment session itself. Researchers and clinicians often place just as much emphasis on what happens before anyone receives a psychedelic substance.
Screening is one of the most important parts of responsible psychedelic-assisted treatment. It helps clinicians understand a person’s medical history, psychiatric history, medications, treatment goals, and potential risk factors before deciding whether a particular treatment may be appropriate.
What Does Screening Usually Involve?
The exact process depends on the treatment and setting. A psilocybin clinical trial may use different eligibility criteria from a medical clinic providing ketamine, while future MDMA-assisted therapy programs may have their own requirements.
In general, screening can include a review of current symptoms, psychiatric diagnoses, medical conditions, medications and supplements, substance use, previous psychedelic experiences, family psychiatric history, treatment history, and expectations for care. The goal is not simply to decide whether someone “qualifies,” but to identify risks and understand whether the proposed treatment fits the person’s clinical situation.
Why Psychiatric History Matters
Psychedelic substances can significantly affect perception, emotion, mood, and cognition. Certain psychiatric histories may therefore require additional caution.
Research studies frequently exclude or carefully evaluate people with histories of psychosis, schizophrenia-spectrum disorders, or particular presentations of bipolar disorder. Family psychiatric history may also be relevant because some vulnerabilities do not become apparent until later in life.
A diagnosis does not automatically determine whether someone could ever receive a particular treatment, but it does make individualized professional evaluation essential.
Bipolar Disorder and Psychosis Require Particular Attention
Researchers are especially cautious about conditions involving mania or psychosis because psychedelic experiences can produce major changes in mood, perception, and thinking. For someone vulnerable to psychiatric destabilization, those effects may present additional risks.
This is why legitimate psychedelic research generally uses detailed inclusion and exclusion criteria. Anyone considering treatment should be cautious about providers who minimize psychiatric history or suggest that screening is unnecessary.
Current Medications Can Affect Treatment
Medication review is another important part of screening. Some psychiatric medications may alter the effects of psychedelic substances, interact with treatment, or create additional medical concerns.
Patients should never stop prescribed medications on their own in order to qualify for a psychedelic experience or clinical trial. Any medication changes should be coordinated with the clinician responsible for prescribing and monitoring those medications.
Physical Health Matters Too
Psychedelic treatment is not exclusively a psychological issue. Some substances can temporarily affect heart rate, blood pressure, or other aspects of physical functioning.
Clinicians may therefore review cardiovascular history, neurological conditions, pregnancy, and other medical issues before treatment. Ketamine also carries its own medical considerations that differ from those associated with psilocybin or MDMA, another reason these therapies should not be treated as interchangeable.
Substance Use History
Substance-use history may also influence screening and treatment planning. The implications depend on the substance, current use, recovery status, the treatment being considered, and the person’s broader psychiatric picture.
This area is more nuanced than simply excluding anyone with a history of addiction because researchers are also studying psychedelic-assisted therapies for substance-use disorders. Active substance misuse, however, can affect safety and needs to be discussed openly.
Expectations Are Part of the Evaluation
Screening is not only about medical exclusions. Expectations matter too.
Someone approaching psychedelic therapy expecting a guaranteed cure after a single session may need a more realistic understanding of the treatment process. Most clinical models involve preparation, supervised treatment, and follow-up rather than a single dramatic experience that permanently resolves a psychiatric condition.
Our article on What Does “Psychedelic-Assisted Therapy” Actually Mean? explains why psychotherapy and clinical support remain central to this field.
Screening Differs by Treatment
Ketamine, MDMA, and psilocybin have different research histories, legal status, pharmacology, and potential risks. A responsible screening process should therefore be specific to the treatment being considered.
Ketamine can currently be prescribed by licensed medical professionals. MDMA-assisted therapy remains under a different regulatory pathway, while psilocybin-assisted therapy is still investigational for psychiatric treatment in California. A single generic “psychedelic screening” checklist is unlikely to capture all of those differences.
Clinical Trials Use Especially Strict Criteria
Clinical trials usually use formal inclusion and exclusion criteria because researchers need to answer specific scientific questions while protecting participants. Potential participants may complete medical assessments, psychiatric interviews, medication reviews, and other evaluations before enrollment.
Being excluded from a study does not necessarily mean someone could never receive psychedelic-assisted treatment in another context. It may simply mean they do not fit the narrowly defined population that particular study is designed to examine.
Our guide to psychedelic clinical trials in California explains the research process in greater detail.
Screening Is Part of Safe Treatment
People eager to access psychedelic therapy may initially view screening as a barrier. In reality, it is better understood as a safety feature.
A thoughtful evaluation may identify medical or psychiatric concerns that should be addressed first, reveal that another treatment is more appropriate, or help clinicians develop a safer and more individualized plan. As psychedelic-assisted therapy becomes more visible, the quality of the screening process may become one of the clearest differences between responsible clinical care and services driven primarily by hype.
Learn More About Psychedelic Therapy in California
Whether you’re exploring treatment options or looking for information specific to your region, continue your research with these guides.
Treatment Guides
- MDMA Therapy in California
- Psilocybin Therapy in California
- Ketamine Therapy
- Psychedelic Integration Therapy
- Psychedelic Clinical Trials California
Regional Guides
- Bay Area Psychedelic Therapy Guide
- Los Angeles Psychedelic Therapy Guide
- Orange County Psychedelic Therapy Guide
- San Diego Psychedelic Therapy Guide
- Sacramento Psychedelic Therapy Guide
- San Jose Psychedelic Therapy Guide
- Silicon Valley Psychedelic Therapy Guide
- Inland Empire Psychedelic Therapy Guide
- Central Coast Psychedelic Therapy Guide